The India-EU API Corridor: USD 2.1 Billion Under the Microscope

The India-EU API trade corridor has a paradox at its heart: India is the most cost-competitive API supplier globally, and the EU is the world most mature generic medicines market — yet the corridor operates well below its potential due to the complexity of EU regulatory requirements.

The corridor by numbers: India exports approximately USD 2.1 billion in APIs to EU annually. Top API categories: antibiotics (penicillin, amoxicillin, azithromycin), cardiovascular (atorvastatin, ramipril), diabetes (metformin, glipizide), analgesics (ibuprofen, paracetamol), and oncology (capecitabine, imatinib). Top EU destinations: Germany (largest — home to Bayer, BASF Pharma, and multiple generics manufacturers), Belgium (Janssen, UCB), Italy (Farmindustria generics cluster), France (Sanofi, SERVIER), Netherlands (Teva Europe HQ).

The two regulatory pathways to EU API market: (1) CEP (Certificate of Suitability from EDQM): submit a dossier demonstrating your API manufacturing process meets Ph. Eur. monograph requirements. Process: 12-18 months, fees approximately EUR 17,000 for new applications. CEP is portable — any EU marketing authorisation holder can reference it. (2) ASMF (Active Substance Master File): for non-pharmacopoeial APIs where manufacturing information needs to be maintained confidentially. Submitted to a national competent authority. Less portable than CEP but sometimes faster to obtain.

EU GMP inspection risk: All API facilities supplying EU must be inspected by EU competent authorities. An unannounced EU GMP inspection resulting in critical or major observations can result in import alert — complete exclusion from EU market without warning. Invest in continuous GMP compliance rather than reactive remediation.